Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states

Cancer Research

Volumn 74, Issue 11, 2014, Pages 2913-2921

  Rahib, Lola ^a   Smith, Benjamin D ^b   Aizenberg, Rhonda ^a   Rosenzweig, Allison B ^a   Fleshman, Julie M ^a   Matrisian, Lynn M ^a  

^a Pancreatic Cancer Action Network   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COLONOSCOPY; COLORECTAL CANCER; EARLY DIAGNOSIS; FEMALE; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MALE; MATHEMATICAL ANALYSIS; MELANOMA; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; THYROID CANCER; TREND STUDY; UTERUS CANCER; AGE; FORECASTING; INCIDENCE; LUNG NEOPLASMS; MORTALITY; PANCREATIC NEOPLASMS; STATISTICAL MODEL; THYROID NEOPLASMS; TRENDS; UNITED STATES;

AGE FACTORS; FEMALE; FORECASTING; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MODELS, STATISTICAL; MORTALITY; PANCREATIC NEOPLASMS; THYROID NEOPLASMS; UNITED STATES;

EID: 84902147062     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0155     Document Type: Review

References (23)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. National Cancer Institute Funded Research Portfolio (NFRP) [Internet]. Bethesda (MD): National Cancer Institute; [cited 2014 April 4]. Available from: http://fundedresearch.cancer.gov.
3. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758-65.
4. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:175-201.
5. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual Report to the Nation on the status of cancer, 1975- 2010, featuring prevalence of comorbidity and impact on survivalamong persons with lung, colorectal, breast, or prostate cancer. Cancer 2013 Dec 16. [Epub ahead of print].
6. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER -Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2010) , National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013.Underlying mortality data provided by NCHS (www.cdc.gov/nchs).
7. Matrisian LM, Aizenberg R, Rosenzweig A. The alarming rise of pancreatic cancer deaths in the United States: whywe need to stemthe tide today. Pancreatic Cancer Action Network. Manhattan Beach, CA: Pancreatic Cancer Action Network; 2012. Available fromhttp://www.pancan.org/section-research/reports/pdf/ incidence-report-2012.pdf.
8. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: A decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659-69.
9. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7.
10. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-73.
11. Davies L, Welch H. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014 Feb 20. [Epub ahead of print].
12. Heller KS. Do all cancers need to be treated? the role of thyroglobulin in the management of thyroid cancer: The 2006 hayes martin lecture. Arch Otolaryngol Head Neck Surg 2007;133:639-43.
13. Welch HG, Black WC. Overdiagnosis in Cancer. J Natl Cancer Inst 2010;102:605-13.
14. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1): S5-16.
15. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: An update. Hepatology 2011;53:1020-2.
16. Spanknebel K, Conlon KC. Advances in the surgical management of pancreatic cancer. Cancer J 2001;7:312-23.
17. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703.
18. Ma J, Siegel R, Jemal A. Pancreatic cancer death rates by race among US men and women, 1970-2009. J Natl Cancer Inst 2013;105: 1694-700.
19. Srivastava S, Gray JW, Reid BJ, Grad O, Greenwood A, Hawk ET, et al. Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. Clin Cancer Res 2008; 14:5672-7.
20. Kaitin KI. Deconstructing the drug development process: The new face of innovation. Clin Pharmacol Ther 2010;87:356-61.
21. Scientific framework for recalcitrant cancers 2013. In: One Hundred Twelfth Congress of the United States of America; 2012 Jan 3; Washington, DC. HR 4310-13:1083. Available fromhttp://www.gpo.gov/fdsys/pkg/BILLS-112hr4310enr/ pdf/BILLS-112hr4310enr.pdf [cited 2014 April 4].
22. deadliestcancers.org. [homepage on the internet]. Pancreatic Cancer Action Network. Available from: http://www.deadliestcancers.org/[cited 2014 April 4].
23. Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). National Cancer Institute; 2014. Available from: http://deainfo.nci.nih.gov/ advisory/ctac/workgroup/pc/PDACframework.pdf [cited 2014 April 4].